Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?

@article{Gritters2008PlateletAI,
  title={Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?},
  author={Mareille Gritters and Piet Borgdorff and Muriel P. C. Grooteman and Marianne Schoorl and M Schoorl and Piet C. M. Bartels and G. -J. Tangelder and Menso J. Nub{\'e}},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2008},
  volume={23 9},
  pages={2911-7}
}
BACKGROUND The sum of undesirable side effects, occurring during haemodialysis (HD), is called bio-incompatibility. Concerning platelets, both an increase in the expression of the cell surface marker P-selectin (CD62p) and release of the intracellular granule product platelet factor 4 (PF4) have been described. However, as PF4 is also abundantly present on endothelium-bound proteoglycans, it is questionable whether the HD-induced increase is exclusively attributable to release from platelets… CONTINUE READING
19 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…